Postoperative Nausea and Vomiting (PONV) Market to Register Sustainable Growth During the Forecast Period - DelveInsight | Key Companies - Heron Therapeutics (APONVIE/aprepitant), Cara Therapeutics, Camurus, Braeburn, and Others

DelveInsight's "Postoperative Nausea and Vomiting Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Postoperative Nausea and Vomiting Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Postoperative Nausea and Vomiting (PONV) market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Postoperative Nausea and Vomiting (PONV): An Overview
Postoperative nausea and vomiting (PONV) is an enormous problem for patients recovering after surgery. About one-third of people experience vomiting, and half of them experience nausea. Nausea, retching, or vomiting usually occurs during the first 24-48 h after surgery in inpatients. Also, PONV is a common side effect following sedation and general anesthesia.

The consequences of PONV can include increased anxiety for future surgical procedures, increased recovery time and hospital stay, and in severe cases, aspiration pneumonia, incisional hernia or suture dehiscence, bleeding esophageal rupture, and metabolic alkalosis.

The Postoperative Nausea and Vomiting market size in the 7MM was found to be USD 1,934.25 Million in 2020, which is expected to increase during the forecast period owing to the increasing population of PONV patients in the 7MM and the launch of emerging therapies. The United States accounts for the highest market size of PONV compared to the other major markets, i.e., EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Postoperative Nausea and Vomiting (PONV) Market Key Facts
• The total population of PONV in the 7MM was 17,264,097 in 2020, which is expected to increase during the study period. Also, the estimates show the highest population of PONV is in the United States, followed by Japan.
• According to an estimate, in 2020, the total cases of PONV included 9,939,406 cases of patients with prophylactic antiemetics: nausea and vomiting, and 2,288,058 cases without it in the United States.
• Among the EU5 countries, in 2020, Germany had the highest population of PONV, followed by Italy, which had a population of 404,997, and Spain had the lowest population of PONV, i.e., 291,610.

Request for Sample PDF:
https://www.delveinsight.com/report-store/postoperative-nausea-and-vomiting-ponv-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Postoperative Nausea and Vomiting (PONV) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Postoperative Nausea and Vomiting market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Postoperative Nausea and Vomiting market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Download the Sample Pages to Discover More About the Report Offerings:
https://www.delveinsight.com/sample-request/postoperative-nausea-and-vomiting-ponv-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Postoperative Nausea and Vomiting (PONV) Epidemiology
The epidemiology section covers detailed insights into the historical and current Postoperative Nausea and Vomiting patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

Postoperative Nausea and Vomiting (PONV) Epidemiology Segmentation
• Total Inpatient Surgeries in the 7MM
• Total Postoperative Nausea and Vomiting (PONV) Cases in the 7MM
• Total Number of Patients with Antiemetic Treatment (prophylactic) or Without Antiemetics Treatment in the 7MM

Postoperative Nausea and Vomiting (PONV) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postoperative Nausea and Vomiting market or expected to get launched in the market during the study period. The analysis covers the Postoperative Nausea and Vomiting market uptake by drugs, patient uptake by therapies, and sales of each drug.

Report's Drugs Uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Postoperative Nausea and Vomiting Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Key Developments in the Postoperative Nausea and Vomiting (PONV) Therapeutics Market
• On September 16, 2022, Heron Therapeutics announced that the US FDA had approved APONVIE (aprepitant) injectable emulsion for intravenous use for the prevention of postoperative nausea and vomiting (PONV) in adults.

Explore More About Pipeline Development Activities:
https://www.delveinsight.com/sample-request/postoperative-nausea-and-vomiting-ponv-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Postoperative Nausea and Vomiting (PONV) Therapeutics Assessment
The available therapeutic treatment options for Postoperative Nausea and Vomiting (PONV) focus on the prevention of PONV. Barhemsys (formerly known as APD421 and Baremsis) was recently approved, and some more emerging therapies, such as CR845 and CAM2058 are under development and expected to launch in the coming years. The launch of the therapies is anticipated to transform the market dynamics.

Some of the key companies in the Postoperative Nausea and Vomiting (PONV) Market include:
• Cara Therapeutics
• Camurus
• Braeburn
• Heron Therapeutics
And many others

Postoperative Nausea and Vomiting Therapies covered in the report include:
• CR845 (difelikefalin) - CR845, which is under development by Cara Therapeutics (also known as difelikefalin) is an analgesic opioid peptide acting as a peripherally specific, highly selective agonist of the kappa opioid receptor.
• CAM2058 - CAM2058, co-developed by Camurus and Braeburn, is a buprenorphine and granisetron combined subcutaneous (SC) depot formulation based on the FluidCrystal injection depot technology.

Learn More About the Emerging Therapies & Key Companies in the Postoperative Nausea and Vomiting Therapeutics Market:
https://www.delveinsight.com/sample-request/postoperative-nausea-and-vomiting-ponv-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Postoperative Nausea and Vomiting Competitive Intelligence Analysis
4. Postoperative Nausea and Vomiting Market Overview at a Glance
5. Postoperative Nausea and Vomiting Disease Background and Overview
6. Postoperative Nausea and Vomiting Patient Journey
7. Postoperative Nausea and Vomiting Epidemiology and Patient Population
8. Postoperative Nausea and Vomiting Treatment Algorithm, Current Treatment, and Medical Practices
9. Postoperative Nausea and Vomiting Unmet Needs
10. Key Endpoints of Postoperative Nausea and Vomiting Treatment
11. Postoperative Nausea and Vomiting Marketed Products
12. Postoperative Nausea and Vomiting Emerging Therapies
13. Postoperative Nausea and Vomiting Seven Major Market Analysis
14. Attribute Analysis
15. Postoperative Nausea and Vomiting Market Outlook (7 major markets)
16. Postoperative Nausea and Vomiting Access and Reimbursement Overview
17. KOL Views on the Postoperative Nausea and Vomiting Market.
18. Postoperative Nausea and Vomiting Market Drivers
19. Postoperative Nausea and Vomiting Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Postoperative Nausea and Vomiting Market report here:
https://www.delveinsight.com/sample-request/postoperative-nausea-and-vomiting-ponv-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/

428, D21 Corporate Park,
Sector-21, Dwarka,
New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.